The Efficacy of Mirabegron as Medical Expulsive Therapy for Distal Ureteral Stones: A Systematic Review and Meta Analysis
DOI:
https://doi.org/10.55927/eajmr.v2i11.6605Keywords:
Mirabegron, Medical Expulsive Therapy, Distal Ureteral StonesAbstract
The aim of this study was to determine how good mirabegron is as MET for adults with ureteral stones. The study adhered to the 2020 PRISMA guidelines for Systematic Reviews and Meta-Analyses throughout its duration. Four randomized controlled trial (RCT) studies were included in our analysis, encompassing a total of 369 participants. Our meta-analysis findings indicated that individuals who were administered mirabegron exhibited a statistically significant increase in SER [OR = 2.69, 95% CI 1.16-6.23, p = 0.02] and a reduction in the frequency of pain episodes [MD= -0.18, 95% CI -0.33-(-0.04), p = 0.01] in comparison to those receiving a placebo. However, there was no substantial impact of mirabegron on SET [MD= -3.47, 95% CI -8.65-1.72, p = 0.19] when contrasted with the placebo group. Mirabegron exhibited significantly increased SET levels and reduced pain episodes, although it did not have a significant impact on SER.
References
Abdelaziz, A. S., & Kidder, A. M. (2017). Tamsulosin therapy improved the outcome of ureterorenoscopy for lower ureteral stones: A prospective, randomised, controlled, clinical trial. African Journal of Urology, 23(2), 148–153. https://doi.org/https://doi.org/10.1016/j.afju.2015.12.003
Bacchus, M. W., Locke, R. A., Kwenda, E. P., DeMarco, R. T., Grant, C., & Bayne, C. E. (2022). Medical Expulsive Therapy (MET) for Ureteral Calculi in Children: Systematic Review and Meta-Analysis. Frontiers in Urology, 2(April), 1–8. https://doi.org/10.3389/fruro.2022.866162
Bayar, G., Yavuz, A., Cakmak, S., Ofluoglu, Y., Kilinc, M. F., Kucuk, E., & Aydın, M. (2020). Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study. International Urology and Nephrology, 52(5), 835–840. https://doi.org/10.1007/s11255-019-02368-y
Cai, D., Wei, G., Wu, P., Huang, Y., Che, X., Zhang, Y., Zhou, Z., & Kong, G. (2022). The Efficacy of Mirabegron in Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis. International Journal of Clinical Practice, 2022, 2293182. https://doi.org/10.1155/2022/2293182
Igawa, Y., & Michel, M. C. (2013). Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn-Schmiedeberg’s Archives of Pharmacology, 386(3), 177–183. https://doi.org/10.1007/s00210-012-0824-1
Lang, J., Narendrula, A., El-Zawahry, A., Sindhwani, P., & Ekwenna, O. (2022). Global Trends in Incidence and Burden of Urolithiasis from 1990 to 2019: An Analysis of Global Burden of Disease Study Data. European Urology Open Science, 35, 37–46. https://doi.org/10.1016/j.euros.2021.10.008
Lim, I., Sellers, D. J., & Chess-Williams, R. (2022). Current and emerging pharmacological targets for medical expulsive therapy. Basic and Clinical Pharmacology and Toxicology, 130(S1), 16–22. https://doi.org/10.1111/bcpt.13613
Malo, C., Audette-Côté, J.-S., Emond, M., & Turgeon, A. F. (2014). Tamsulosin for treatment of unilateral distal ureterolithiasis: a systematic review and meta-analysis. CJEM, 16(3), 229–242. https://doi.org/10.2310/8000.2013.131012
Matsumoto, R., Otsuka, A., Suzuki, T., Shinbo, H., Mizuno, T., Kurita, Y., Mugiya, S., & Ozono, S. (2013). Expression and functional role of β3-adrenoceptors in the human ureter. International Journal of Urology, 20(10), 1007–1014. https://doi.org/10.1111/iju.12093
Sayed, M. A.-B., Moeen, A. M., Saada, H., Nassir, A., Tayib, A., & Gadelkareem, R. A. (2022). Mirabegron as a Medical Expulsive Therapy for 5-10 mm Distal Ureteral Stones: A Prospective, Randomized, Comparative Study. Turkish Journal of Urology, 48(3), 209–214. https://doi.org/10.5152/tud.2022.22014
Shen, H., Chen, Z., Mokhtar, A. dhabi, Bi, X., Wu, G., Gong, S., Huang, C., Li, S., & Du, S. (2017). Expression of β-adrenergic receptor subtypes in human normal and dilated ureter. International Urology and Nephrology, 49(10), 1771–1778. https://doi.org/10.1007/s11255-017-1667-y
Solakhan, M., Bayrak, O., & Bulut, E. (2019). Efficacy of mirabegron in medical expulsive therapy. Urolithiasis, 47(3), 303–307. https://doi.org/10.1007/s00240-018-1075-5
Sorokin, I., Mamoulakis, C., Miyazawa, K., Rodgers, A., Talati, J., & Lotan, Y. (2017). Epidemiology of stone disease across the world. World Journal of Urology, 35(9), 1301–1320. https://doi.org/10.1007/s00345-017-2008-6
Sun, Y., Lei, G.-L., Yang, L., Wei, Q., & Wei, X. (2019). Is tamsulosin effective for the passage of symptomatic ureteral stones. Medicine, 98(10), e14796. https://doi.org/10.1097/md.0000000000014796
Tang, Q. lai, Wang, D. jian, Zhou, S., & Tao, R. zhen. (2021). Mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study. World Journal of Urology, 39(12), 4465–4470. https://doi.org/10.1007/s00345-021-03772-9
Türk, C., Petřík, A., Sarica, K., Seitz, C., Skolarikos, A., Straub, M., & Knoll, T. (2016). EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. European Urology, 69(3), 468–474. https://doi.org/10.1016/j.eururo.2015.07.040
Urkmez, A., Tokuc, E., Topaktas, R., Sahin, A., & Yuksel, O. H. (2019). Mirabegron: A novel and promising medical expulsive treatment for ureteral stones? Journal of the College of Physicians and Surgeons Pakistan, 29(1), 73–74. https://doi.org/10.29271/jcpsp.2019.01.73
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 I Gede Yogi Prema Ananda, Radika Naufal Hadi Surya, Alfin Putratama, Prima Ardiansah Surya, R. Mohamad Javier, Saidah Rahmat, Eko Setyo Herwanto, Rachmat Budi Prasetyo
This work is licensed under a Creative Commons Attribution 4.0 International License.
.png)
